Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.31 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.31 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21933931 | 0.83 | KDM4E (0.38) | KDM4ENPC1 | |
| SCHEMBL10244655 | 0.81 | HSD11B1 (0.39) | KDM4ENPC1PSMB1PSMB5PSMB2 | |
| SCHEMBL6656278 | 0.79 | ALOX15 (0.36) | KDM4E | |
| SCHEMBL9611073 | 0.79 | ALOX15 (0.36) | KDM4E | |
| SCHEMBL19598493 | 0.79 | ALDH1A1 (0.36) | KDM4ENPC1PSMB1PSMB5PSMB2 | |
| SCHEMBL20161015 | 0.78 | — | — | |
| SCHEMBL21386592 | 0.78 | ALDH1A1 (0.40) | KDM4ENPC1 | |
| SCHEMBL16019930 | 0.78 | CYP2D6 (0.35) | KDM4ECYP2D6CYP2C19HSD17B10 | |
| SCHEMBL22150445 | 0.76 | ALDH1A1 (0.34) | KDM4E | |
| SCHEMBL21421833 | 0.76 | KDM4E (0.34) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210040486-A1 | INTRACELLULAR KINASE ASSOCIATED WITH RESISTANCE AGAINST ANTI-TUMOUR IMMUNE RESPONSES, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040486-A1 | INTRACELLULAR KINASE ASSOCIATED WITH RESISTANCE AGAINST ANTI-TUMOUR IMMUNE RESPONSES, AND USES THEREOF | SIK3, SIK1, SIK2 | KDM4E 3132/4885NPC1 3517/4885PSMB1 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.